Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.
Myeloma|Multiple Myeloma
DRUG: Daratumumab|DRUG: Carfilzomib|DRUG: Lenalidomide|DRUG: Dexamethasone
Rate of stringent complete response (sCR), 8 months|Rate of minimal residual disease (MRD)-negative disease as assessed by Next Generation Sequencing, 8 months
Long term rate of MRD-negative disease, 2 years|Duration of response, 1 year|Rate of progression free survival, 2 years|Time to progression, 2 years|Overall survival rate, 2 years|Overall response rate, 2 years|Number of grade 2 or higher side effects as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 criteria, 8 months
The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.